Diagnostic Cervical Conization for Persistent Infection or Integration of HPV
Launched by TONGJI HOSPITAL · Aug 19, 2022
Trial Information
Current as of June 27, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a procedure called cervical conization, which is used to remove a small piece of tissue from the cervix. This procedure is designed for women who have a persistent infection with certain types of the Human Papillomavirus (HPV) or signs that the virus may be affecting their cervical health. The goal is to help doctors diagnose and treat conditions related to HPV, including precancerous changes and cervical cancer, more effectively.
To be eligible for this trial, women need to have had abnormal cervical screening results that did not show any precancerous lesions but are still considered at risk due to factors such as a long-term HPV infection or specific findings during a pelvic exam. However, pregnant women and those with certain health issues or other types of cancer cannot participate. If eligible, participants can expect to undergo the cervical conization procedure, which will be closely monitored to ensure their safety and to gather important information about HPV and cervical health. This trial aims to improve the understanding and treatment of HPV-related conditions in women.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1. The patients are referred to colposcopy and biopsy examinations due to abnormal cervical screening results with no precancerous lesions discovered by pathology.
- 2. The cervical precancerous lesions are highly suspected by clinicians with one or more following risk factors:
- • The course of HPV type 16/18 persistent infection is more than two years.
- • The integration reads of HPV is more than 15.
- • The impression of colposcopy indicates precancerous lesions.
- • The cervical TCT indicates ASC-H/HSIL/SCC/AGC-FN/AIS/AC.
- Exclusion Criteria:
- • 1. Pregnant women.
- • 2. Vaginal intraepithelial neoplasia is highly suspected by colposcopy and pathological examinations.
- • 3. The patients are suffering malignant tumors of other system and have not been cured.
- • 4. There is acute inflammation of the lower genital or anal tract.
- • 5. The patients' health will be severely harmed by the colposcopy and cervical conization due to some circumstances such as severe insufficiency of liver and kidney function, blood diseases and acute inflammation of other systems.
About Tongji Hospital
Tongji Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology, is a leading medical institution in China dedicated to advancing healthcare through innovative research and clinical trials. With a robust infrastructure and a multidisciplinary team of experts, Tongji Hospital focuses on translating scientific discoveries into effective treatments and therapies. The hospital is committed to enhancing patient care by conducting rigorous clinical trials that adhere to the highest ethical and regulatory standards, fostering collaboration with both national and international research communities to drive medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Wuhan, Hubei, China
Patients applied
Trial Officials
Shuang Li, M.D
Principal Investigator
Tongji Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials